TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03288948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binocular games for treatment of amblyopia
Description: playing binocular games on a tablet platform 1 hour per day 5 days per week with reduced contrast for the fellow eye and high contrast for the amblyopic eye

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binocular games for treatment of amblyopia
Description: playing binocular games on a tablet platform 1 hour per day 5 days per week with reduced contrast for the fellow eye and high contrast for the amblyopic eye

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Binocular games for treatment of amblyopia
Description: playing binocular games on a tablet platform 1 hour per day 5 days per week with reduced contrast for the fellow eye and high contrast for the amblyopic eye
Study: NCT03744182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM15211
Description: A sterile solution of HM15211 contained in pre-filled syringes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of HM15211
Description: A sterile, matching solution in pre-filled syringes
Study: NCT01823159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: retigabine
Description: Single oral administration of a 400 mg tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single oral administration of a tablet
Study: NCT01832129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of vitamin B12
Description: Daily high dose oral vitamin B12 (1mg) will be administered over 4 weeks. The patients adherence to this regimen will be monitored with an electronic punch card.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: i.m. injection of vitamin B12
Description: Intramuscular injections of 1 mg vitamin B12 will be performed at days 7, 14, and 21.
Study: NCT03344848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orion Visual Cortical Prosthesis System
Description: The Orion Visual Cortical Prosthesis System is intended to stimulate the medial surface of the occipital lobe in the visual cortex to induce visual perception in blind individuals.
Study: NCT03501576

Intervention type: BIOLOGICAL
Intervention: Inactivated Influenza Vaccine
Description: Given seasonal inactivated influenza vaccine IM
Study: NCT04313374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine PCA 1 mg
Description: PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine PCA 0,5 mg
Description: PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the PCA will contain placebo
Study: NCT01490736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemuteporfin
Description: lemuteporfin topical solution, 1%
Study: NCT04357730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase 50 MG [Activase]
Description: Patients randomized to Alteplase-50 group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours, given as a 10 mg push followed by the remaining 40 mgs over a total time of 2 hrs. Immediately following the Alteplase infusion, 5000 units (U) of unfractionated heparin (UFH) will be delivered and the heparin drip will be continued to maintain the activated partial thromboplastin time (aPTT) at 60-80sec (2.0 to 2.5 times the upper limit of normal). Re-bolusing of Alteplase, at the same dose, is permitted in the Alteplase-50 intervention group in those patients who show an initial transient response (\>20% improvement of PaO2/FiO2 over pre-infusion of Alteplase at any of the measurements at 2, 6, 12 or 18 hours, but \<50% improvement of PaO2/FiO2 at 24 hours after randomization); the repeat dose will be given between 24 and 36 hours after the initial Alteplase administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase 50 MG [Activase]
Description: wed by the remaining 40 mgs over a total time of 2 hrs. Immediately following this initial Alteplase infusion, we will initiate a drip of 2 mg/hr Alteplase over the ensuing 24 hours (total 48 mg infusion) accompanied by an infusion of 500 units per hour (U/hr) heparin during the Alteplase drip. After this, heparin dose will be increased slowly to maintain aPTT between 60 and 80 sec, titrated per attending's discretion.
Study: NCT01723293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: The physical conditioning program included a total of three 55-60 minute sessions per week. Pregnant women started in 9-12 weeks and finished in 38-40 weeks, therefore, an average of 85 training sessions were planned for each participant. All subjects wore a heart rate (HR) monitor (Polar FT7, Finland) during the training sessions to ensure that the exercise intensity was light to moderate.~Each session included a 25-minutes of aerobic exercise, 10-minutes of strength exercise and balance exercise as well, and 10-minutes of pelvic floor muscles training.
Study: NCT03135769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab administration at 10mg/kg
Description: Avelumab administration at 10 mg/kg as a 1 hour IV infusion once every 14 days during 6 months (maximum).
Study: NCT04746586

Intervention type: OTHER
Intervention: Circulating MiRNA indentification
Description: Identification of circulating miRNA useful to discriminate between worsening and stable forms of AIS

Intervention type: OTHER
Intervention: Circulating MiRNA indentification
Description: Identification of circulating miRNA useful to discriminate between worsening and stable forms of AIS
Study: NCT00345046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate
Description: Dosed four times daily decreasing to once daily over four weeks.
Study: NCT04681794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise-based intervention
Description: MayoP4 is a 15-minute warmup with 4 different components of exercise: balance, posture, jumping/hopping, and movement-based mindfulness.
Study: NCT01754051

Intervention type: DEVICE
Intervention: PC 400 coils
Study: NCT04383067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Patient with metastatic urothelial carcinoma will undergo a autologous lymphocyte transplantation. Patient will undergo surgery to remove either the primary tumor or a tumor metastasis. The cells collected in this surgey will be cultured and reintroduced to the patient. Following the cell infusion, patient will receive a high-dose bolus of IL-2.
Study: NCT00685269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone
Description: Eszopiclone 3 mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT01074463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole Dihydrochloride
Description: 0.25 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole Dihydrochloride
Description: 0.25 mg Tablet
Study: NCT04495257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg intravenously (IV) every 3 weeks for the first 4 treatments and then will be given at 360mg every 3 weeks thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg intravenously (IV) every 3 weeks for the first 4 treatments and then will be given at 360mg every 3 weeks thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1mg/kg intravenously (IV) every 3 weeks for a total of 4 treatments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1mg/kg intravenously (IV) every 3 weeks for a total of 4 treatments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: APX005M 0.3mg/kg intravenously (IV) every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: APX005M 0.3mg/kg intravenously (IV) every 3 weeks
Study: NCT04186988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Ara-G
Description: Given IV
Study: NCT02101788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study: NCT03401021

Intervention type: OTHER
Intervention: Questionnaires set
Description: Participants will be asked to respond to the demographic information sheet, Smoking characteristics sheet, the Fagerstrom Test of Nicotine Dependence, the Transtheoretical Model (TTM) variables, Smoking Self-efficacy Questionnaire (SEQ-12), Family Adaptation, Partnership, Growth, Affection, and Resolve (Family APGAR), and a smoking hazard questionnaire.
Study: NCT01205061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emervel Deep Lidocaine
Description: 20 mg/mL + 0.3% lidocaine
Study: NCT03355651

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PROGEN
Description: Dietary supplement based on plasma proteins, hydrolyzed collagen, a complex of Hyaluronic Acid - Chondroitin Sulfate (HC-15), and vitamin C
Study: NCT02855333

Intervention type: OTHER
Intervention: EORTC and QLQ-C30 / QLQ-OES24 questionnaire
Description: EORTC and QLQ-C30 / QLQ-OES24 questionnaire was sent to patients to asses QoL after MER or CON procedure

Intervention type: OTHER
Intervention: EORTC and QLQ-C30 / QLQ-OES24 questionnaire
Description: EORTC and QLQ-C30 / QLQ-OES24 questionnaire was sent to patients to asses QoL after MER or CON procedure
Study: NCT01138033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256098
Description: GSK2256098 is a potent focal adhesion kinase inhibitor that will be administered orally as 20, 100 or 250 mg capsules. The starting dose in Part 1 is 80 mg twice daily. The dose will continue to be increased until the maximum tolerated dose is identified.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256098
Description: GSK2256098 is a potent focal adhesion kinase inhibitor that will be administered orally as 20, 100 or 250 mg capsules. The starting dose in Part 1 is 80 mg twice daily. The dose will continue to be increased until the maximum tolerated dose is identified.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256098
Description: GSK2256098 is a potent focal adhesion kinase inhibitor that will be administered orally as 20, 100 or 250 mg capsules. The starting dose in Part 1 is 80 mg twice daily. The dose will continue to be increased until the maximum tolerated dose is identified.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256098
Description: GSK2256098 is a potent focal adhesion kinase inhibitor that will be administered orally as 20, 100 or 250 mg capsules. The starting dose in Part 1 is 80 mg twice daily. The dose will continue to be increased until the maximum tolerated dose is identified.
Study: NCT02820987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEROPENEM
Description: Administration of MEROPENEM according to a protocol of extended infusion defining dose and duration of infusion.
Study: NCT01138033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256098
Description: GSK2256098 is a potent focal adhesion kinase inhibitor that will be administered orally as 20, 100 or 250 mg capsules. The starting dose in Part 1 is 80 mg twice daily. The dose will continue to be increased until the maximum tolerated dose is identified.
Study: NCT00298051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping
Study: NCT00863603

Intervention type: OTHER
Group type: OTHER
Intervention: oxygen
Description: 5 Liter/minute by nasal cannula for 6 wks
Study: NCT04383067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proleukin
Description: high-dose (720,000 IU/kg) IL-2 will be administered every 8 hours, to tolerance. A maximum of 10 doses will be administered
Study: NCT03150875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308
Description: Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.
Study: NCT02820987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PIPERACILLIN-TAZOBACTAM
Description: Administration of PIPERACILLIN-TAZOBACTAM according to a protocol of continuous infusion defining dose and duration of infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEFEPIME
Description: Administration of CEFEPIME according to a protocol of continuous infusion defining dose and duration of infusion.
Study: NCT03150875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: As 2nd line treatment to subjects with squamous NSCLC
Study: NCT02101788

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen Citrate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO
Study: NCT04250155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb24306
Description: Participants will receive intravenous (IV) XmAb24306.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb24306
Description: Participants will receive intravenous (IV) XmAb24306.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive IV XmAb24306 followed by IV atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive IV XmAb24306 followed by IV atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb24306
Description: Participants will receive IV XmAb24306 followed by IV atezolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb24306
Description: Participants will receive IV XmAb24306 followed by IV atezolizumab.
Study: NCT01322867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam tablet
Description: 0,25 mg oral tablets given once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam oral solution
Description: 0,75 mg/ml Oral Solution (Drops) given once
Study: NCT00670202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil Hydrochloride
Description: Fasudil 40 mg three times a day x 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo oral tablet manufactured to mimic fasudil three times a day x 14 days
Study: NCT03357718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex
Description: 2 µg/kg oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 0.5 mg/kg
Study: NCT04380090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propylene Glycol
Description: Patients in the propylene glycol arm will receive one standard dose of the drug on postoperative day one prior to discharge with the aim of decreasing rates of postoperative constipation for patients following single total knee replacement surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docusate Sodium
Description: Patients in the docusate sodium arm are receiving the current standard of care for prevention of postoperative constipation following single total knee replacement surgery, docusate sodium one pill twice a day by mouth for 28 days
Study: NCT03392987

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OTL-200
Description: OTL-200 is an autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human ARSA cDNA sequence
Study: NCT00702533

Intervention type: DEVICE
Intervention: Pentagastrin Injection BP

Intervention type: DEVICE
Intervention: Pentagastrin Injection BP
Study: NCT01205061

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvederm Ultra Plus
Description: 24mg/mL
Study: NCT01520701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bandage skin Hydrotac®
Description: Patients randomized to the arm with bandage skin will benefit from the application of the bandage skin hydrogel (Hydrotac®) at least 5 hours per day for the duration of treatment (the first day last day of radiotherapy).
Study: NCT03629756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist.
Study: NCT01520701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ialuset®
Description: Patients randomized to receive reference of the application of cervical Ialuset® on skin throughout the treatment period (the first day to last day of radiotherapy).
Study: NCT03327220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iovera°
Description: The iovera° device applies cold to a target nerve to cause a temporary peripheral nerve block based on a process called Wallerian degeneration (2nd degree axonotmesis) without disrupting connective nerve tissue.
Study: NCT03960411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 100Mg Capsule
Description: Doxycycline capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Capsule manufactured to mimic doxycycline 100 mg capsule
Study: NCT01686425

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous transhepatic cholangiography vs. endoscopic biliary drainage
Description: Percutaneous transhepatic cholangiography biliary drainage is compared tot endoscopic biliary drainage in the management of malignant biliary obstruction not amenable to ERCP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous transhepatic cholangiography vs. endoscopic biliary drainage
Description: Percutaneous transhepatic cholangiography biliary drainage is compared tot endoscopic biliary drainage in the management of malignant biliary obstruction not amenable to ERCP
Study: NCT01693341

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care-giver mediated training
Description: A physical therapist visited each subject and the caregiver (of the intervention group) once weekly for about 90 min/session to teach patient-skills and caregiver-skills. The therapist first reviewed the condition of each patient and planned patient-specific training programs, continuously performed 12 weeks.
Study: NCT00551148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: oral 15 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: oral 30 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: oral 5 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: oral 60 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
Study: NCT03425006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: a JAK 1 selective small molecule inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: a highly selective humanized monoclonal antibody (mAb)
Study: NCT02383654

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autologous Adipose-Tissue Derived Stem Cells
Description: 1. Intravenous and Intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells~2. Patient will receive brain implantation of approximately 100 -400million Autologous Adipose-Tissue Derived Stem Cells.~Patient will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice , before brain implantation, and will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice, after brain implantation .
Study: NCT00646763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF, GM-CSF administered at extremities
Description: Injection site Extremities: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a twice daily schedule of G-CSF/GM-CSF until stem cell collection is complete.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF and GMCSF administered at abdomen
Description: Injection site Abdomen: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a BID schedule of G-CSF/GM-CSF until stem cell collection is complete.
Study: NCT01676753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinaciclib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01076868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Primaquine x 14 days
Study: NCT01345513

Intervention type: OTHER
Intervention: Sample Collection for Genome-Wide Sequencing
Description: Collection of archival tumor tissue, fresh tumor biopsy, blood sample, and pleural effusion (if available)or ascites (if available)
Study: NCT02899650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: acute downhill running
Study: NCT03629756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist.
Study: NCT00432471

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optical Imaging
Description: Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.